The July 2026 FDA Vote on Compounded Peptides: What It Changes for Tracking
6 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
The Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to vote on the 503A bulk-substance status of several peptides currently sourced from compounding pharmacies. The outcome will reshape access for protocol users, especially those running BPC-157, TB-500, and the growth-hormone-axis stack. This guide walks the likely scenarios, what to start tracking before the vote, and how miora handles a mid-protocol supply disruption.
Topics on this page
The PCAC vote does not directly ban peptides; it affects which compounds pharmacies can legally compound under 503A. The supply chain consequence is real even if the regulatory language is narrow.
Inventory matters more than usual. Knowing exactly how many vials, what concentration, and what expiration is the difference between an orderly transition and an interrupted protocol.
Cycle position is the second-most-important data point. A protocol that is two weeks into a healing cycle responds differently to a forced pause than one in week seven of eight.
Peptide compounding has lived in an awkward regulatory grey zone for years. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to vote on July 23-24, 2026 on whether several peptides currently being compounded under 503A status will remain on the approved bulk-substances list. The exact agenda is in the Federal Register notice for the meeting; the practical consequence is that any peptide removed from the 503A list becomes substantially harder for compounding pharmacies to source and dispense. This guide is a practical walk-through of what changes for tracking, what to log before the vote, and what to do with the data if access changes.
The Pharmacy Compounding Advisory Committee is a federal advisory committee that recommends to the FDA which bulk substances are appropriate for 503A compounding. 503A is the section of the Food Drug and Cosmetic Act that allows pharmacies to compound medications for individual patients with a prescription. The committee's vote is advisory; the FDA can accept, modify, or reject the recommendation. In practice, the FDA usually follows committee recommendations within 12 to 18 months.
The July 2026 meeting is scheduled for two days and the public agenda lists nominations and reviews of several peptides currently being compounded. The specific peptides on the docket vary by meeting; users running BPC-157, TB-500, growth-hormone-axis stacks (CJC-1295, ipamorelin, sermorelin), and certain repair peptides should treat the meeting as relevant. The FDA meeting page and the Federal Register notice are the authoritative sources for the final agenda.
The committee can vote three practical ways on each substance: include on the 503A list (substance can be compounded), exclude from the list (compounding pharmacies should not compound it under 503A), or defer for further evaluation. A vote to exclude does not immediately criminalize the substance; it removes the legal cover compounding pharmacies have been operating under, which has predictable downstream effects on pharmacy decisions about whether to continue dispensing.
Three scenarios are worth being prepared for, in roughly descending order of likelihood.
Scenario one: status quo. The committee defers, or includes the peptides being voted on, or limits the exclusion to a few less-common substances. Most users running standard protocols experience no immediate change. The right response is to keep the tracking and inventory data anyway, because the regulatory direction over multiple meetings has been tightening.
Scenario two: partial exclusion. One or two specific peptides are excluded - most commonly the lesser-evidenced or higher-risk compounds. Pharmacies stop compounding those specific peptides within a few months. Users running protocols including those compounds need a wind-down or transition plan, ideally before pharmacy supply tightens.
Scenario three: broad exclusion. Multiple peptides excluded simultaneously, including widely-used ones. Pharmacies face a meaningful compounding-business shift; users face access disruption within months. The wind-down plan needs to be ready before the vote, not after.
In all three scenarios, the data you have collected up to the vote determines how cleanly the transition can happen. Cycle position, dose history, side-effect log, lab trends, and current inventory are all inputs to the clinician conversation that follows.
Five things worth having structured by mid-July, regardless of which scenario plays out.
Current inventory. Vials of each compound, concentration, reconstitution status, and expiration. Most users can name what they are running; few can name exactly how much of it they have. miora maintains the inventory log automatically as each dose is logged.
Cycle position. Which compound is in which week of which cycle. If a cycle is in week 6 of 8, the wind-down looks different than if it is in week 2 of 8.
Side-effect history. The six-dimension daily log over the protocol. This becomes the baseline that any post-vote change is measured against.
Outcome data. Whatever you have been tracking as the protocol goal - weight, body composition, recovery markers, lab values, subjective metrics. Trends across the protocol.
Clinician-ready protocol summary. A one-page export of the above. If you need to have an unscheduled conversation with your prescriber in late July or early August, this summary saves the visit.
miora can generate the clinician-ready summary on request at any time. The other four are accumulated automatically through the daily and weekly logging.
If your protocol includes a compound that gets voted off the 503A list, three immediate steps:
First, finish or pause the current cycle on your clinician's guidance. Abruptly stopping mid-cycle is rarely the right move; finishing the cycle with current inventory and then transitioning is usually preferable. Your prescriber's input matters here. The structured cycle data makes that conversation faster.
Second, inventory becomes the operative variable. Knowing exactly how much of the compound you have left, at what concentration, with what expiration, determines how many more cycles are realistic. miora's inventory log makes this trivial; without it, the next pharmacy conversation is a guess.
Third, the transition protocol is a clinician decision. Some compounds have viable substitutes; some do not. Some protocols can pause and resume on a different substance; some cannot. miora does not recommend substitutes or transitions; the data exists to support whatever decision you and your prescriber make.
The miora workflow for a supply disruption is straightforward and starts before the disruption happens.
Before the vote. Daily logging continues as normal. Inventory updates automatically with each dose. A pre-vote clinician summary can be generated on demand. miora will text a reminder one week before July 23 to confirm inventory and cycle position.
During the vote week. The agenda is updated in the morning text on July 23 and 24. If a compound you are running is on the docket, miora flags it and surfaces the current cycle position and inventory in the morning summary.
After the vote. If a compound is excluded, the next morning summary opens with the regulatory change, your remaining inventory, your current cycle week, and the suggested next clinician question. The actual decision belongs with you and your prescriber. miora does not recommend transitions, substitutes, or alternative sources. The compounder-shutdown guide walks the related scenario of a pharmacy ceasing operations independent of regulatory change.
BPC-157 is the peptide most users are asking about in connection with the July vote. The substance has been compounded under 503A for years, has a large community user base, and lacks the kind of large-scale clinical trial data that would make a positive vote a foregone conclusion. The committee's prior reviews of healing peptides have leaned cautious.
For BPC-157 users specifically, the tracking priorities before the vote: cycle position (BPC is usually run in 4 to 8 week cycles), injection-site rotation log (BPC is often injected at or near the site of injury, and rotation matters), symptom and outcome data for the indication (sleep, recovery, soft-tissue healing, GI - BPC is used for several distinct goals), and current vial inventory.
The BPC-157-specific guide walks the wind-down or transition scenarios in more detail. miora supports BPC tracking including indication-specific symptom dimensions (for example, soft-tissue pain on a 1-to-5 scale for users running BPC for injury recovery).
One forward-looking consideration. A regulatory environment that is tightening makes the protocol log a more sensitive document over time. Best practice for protocol users:
Keep data in your control. A peptide log stored on a consumer app's server is in someone else's control. miora's iMessage architecture keeps the thread on your phone, encrypted in transit by Apple, with no marketing-data server in the loop.
Be intentional about clinician sharing. The clinician-ready summary is an explicit export. Sharing is your choice; the default is private.
Maintain inventory documentation. Receipts, pharmacy records, lab dates. miora does not store these, but the protocol log makes their cross-reference straightforward.
Understand your jurisdiction. Compounding regulations vary by state and by country. The PCAC vote is a US federal action; users outside the US may have different regulatory dynamics. miora's tracking is jurisdiction-agnostic; the data is the same regardless of where you are.
Three explicit boundaries.
This guide is not legal advice. The 503A regulatory framework is complex and the implications of a PCAC vote depend on FDA action, pharmacy interpretation, and individual state regulations. For specific legal questions about peptide access in your jurisdiction, consult a qualified attorney.
This guide is not medical advice. miora does not prescribe, recommend, source, or suggest peptides; does not recommend cycles, doses, or compounds; and does not suggest substitutes for compounds that may become restricted. All protocol decisions belong with your prescriber.
This guide does not predict the vote outcome. The PCAC committee's deliberations are independent and the vote will be what it is. The point of pre-vote tracking is to be prepared for any of the three scenarios with structured data, not to bet on one outcome over another. This content is for informational purposes only and is not medical or legal advice. Peptides are not FDA-approved supplements. Consult qualified professionals for protocol and regulatory questions.
94
